MindWalk Holdings Corp.
HYFT evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for HYFT—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · HYFT
MindWalk Holdings Corp. (HYFT) is a biotechnology company that combines AI-driven drug discovery platforms (HYFT® and LensAI™) with wet-lab antibody services, advancing a proprietary pipeline in oncology, immunology, neurology, and infectious disease while also providing discovery and development services to clients.
Key risk: Going concern risk
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Financial data as of Jan 31, 2026.
MindWalk Holdings Corp. (HYFT) is a biotechnology company that combines AI-driven drug discovery platforms (HYFT® and LensAI™) with wet-lab antibody services, advancing a proprietary pipeline in oncology, immunology, neurology, and infectious disease while also providing discovery and development services to clients.
- The company has active Phase 1 through Phase 3 clinical trials, including four first-in-class programs, across oncology, immunology, neurology, and infectious disease [sec · filed 2026-07-23].
- Cash and equivalents were $14.1M as of 2026-01-31 [sec].
- Total revenue was $4.2M with a net loss of -$3.9M for the period ended 2026-01-31 [sec].
- The company's platforms include the patented HYFT® technology and LensAI™ epitope mapping platform, used for both client services and internal pipeline development [sec · filed 2026-07-23].
- The company has over 400 peer-reviewed publications and patents supporting its technology [sec · filed 2026-07-23].
What works
- The company has a track record of advancing multiple clinical-stage assets (four first-in-class) through its discovery and wet-lab capabilities, which are also available to clients [sec · filed 2026-07-23].
- Its proprietary HYFT® and LensAI™ platforms are integrated with AI-driven tools, enabling in silico discovery, epitope mapping, and antibody engineering [sec · filed 2026-07-23].
- The company is one of the few approved CROs for multiple transgenic animal providers, supporting market acceptance of its services [sec · filed 2026-07-23].
What to weigh
- The company has historically incurred net losses and its cash reserves may not be sufficient to fund operations for the next twelve months, raising substantial doubt about its ability to continue as a going concern [sec · filed 2026-07-23].
- The company relies on out-licensing its early-stage candidates prior to clinical trials, meaning commercial success depends on securing and maintaining favorable collaborations [sec · filed 2026-07-23].
- The company faces intense competition for experienced scientists and may be unable to attract or retain key personnel [sec · filed 2026-07-23].
From the filings
Quoted directly from source documents.
The company has active Phase 1 through Phase 3 clinical trials, including four first-in-class programs.
“in active Phase 1 through Phase 3 clinical trials, four of them first-in-class, across oncology, immunology, neurology, and infectious disease.”
SEC filings · July 23, 2026
The company may not have sufficient cash reserves to fund operations for the next twelve months.
“sufficient cash reserves to fund our operations for the next twelve months, which raises substantial doubt about our ability to continue as a going concern.”
SEC filings · July 23, 2026
The company relies on out-licensing its early-stage candidates.
“of our early-stage candidates ourselves and instead aim to out-license assets prior to clinical trial research, which means the advancement and commercial potential of our internal programs may depend substantially on our ability to secure and maintain favorable collaborations, licenses or other strategic arrangements.”
SEC filings · July 23, 2026
Risks & what to watch (4)›
Key risks
- Going concern risk — The company may not have sufficient cash to fund operations for the next twelve months, raising substantial doubt about its ability to continue as a going concern [sec · filed 2026-07-23].
- Dependence on collaborations — The company out-licenses early-stage candidates, so commercial success depends on securing and maintaining favorable collaborations [sec · filed 2026-07-23].
- Negative operating cash flow — The company has historically incurred net losses and may need to raise additional capital through share issuances or debt [sec · filed 2026-07-23].
- Regulatory and AI compliance — The company is subject to evolving data privacy and AI regulations (GDPR, CCPA) and any failure to comply could result in penalties [sec · filed 2026-07-23].
What to watch
- Advancement of the universal dengue vaccine program to pre-clinical manufacturing and in vivo testing [sec · filed 2026-07-23].
- Progress of the AI-designed GLP-1 therapeutics program and any new insights from the LensAI™ platform [sec · filed 2026-07-23].
- Ability to secure additional financing or strategic partnerships to address going concern risk [sec · filed 2026-07-23].
- Milestone achievements in the company's proprietary pipeline of AI-optimized therapeutics [sec · filed 2026-07-23].
Sources: SEC filings · Generated August 18, 2026 · How we verify sources →
Run MindWalk Holdings Corp. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available MindWalk Holdings Corp. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 2 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
10.7 months
D/E 0.55
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
25
Total value held
$1.7M
| Holder | Shares | Value |
|---|---|---|
| susquehanna international group, llp | 544,916 | $616K |
| renaissance technologies llc | 232,480 | $263K |
| xtx topco ltd | 172,547 | $195K |
| citadel advisors llc | 147,907 | $167K |
| jane street group, llc | 126,552 | $143K |
| bank of montreal /can/ | 69,947 | $79K |
| bridgeway capital management, llc | 50,000 | $57K |
| allianz asset management gmbh | 35,000 | $40K |
| gradient capital advisors, llc | 26,551 | $30K |
| marshall wace, llp | 25,246 | $29K |
Showing top 10 of 25 institutional holders of MindWalk Holdings Corp.. Open the full 13F history after sign-in.
Short Interest
as of May 21, 2026- % of float
- 1.8%
- Days to cover
- 4.2
- Shares short
- 811,763
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
HYFT short interestFrequently asked questions
What is the AI investment thesis for MindWalk Holdings Corp.?
MindWalk Holdings Corp. (HYFT) is a biotechnology company that combines AI-driven drug discovery platforms (HYFT® and LensAI™) with wet-lab antibody services, advancing a proprietary pipeline in oncology, immunology, neurology, and infectious disease while also providing discovery and development services to clients.
Who is the CEO of MindWalk Holdings Corp.?
Dr. Jennifer Lynne Bath Ph.D. is the chief executive officer of MindWalk Holdings Corp. (HYFT).
Where is MindWalk Holdings Corp. headquartered?
MindWalk Holdings Corp. (HYFT) is headquartered in Austin, TX, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.